A Phase 2 trial update pushed a Canadian biopharma stock higher Thursday. Here’s some small stocks making big moves on Thursday, March 19, 2020 (as of 11:30 am EST):
BELLUS Health Inc. (TSX:BLU), a Canadian biopharma stock, climbed 21% to $11.40 on Thursday after announcing that it has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in patients with refractory chronic cough.
As well, shares of SunOpta Inc. (TSX:SOY) surged 34% to $3.07 as the organic foods and ingredients provider said it expects its first-quarter 2020 Adjusted EBITDA to double year over year to a range of between $21 million to $25 million.
Reliq Health Technologies Inc. (TSXV:RHT), meanwhile, reported that it continues to provide the full range of iUGO Care software solutions and services to its clients remotely and its clients are able to use the iUGO Care platform to communicate virtually with their patients, monitor patients’ existing chronic conditions, evaluate patients for symptoms of COVID-19 infection and document risk factors such as travel or exposure to anyone who has tested positive for the virus. Reliq Health Technologies stock moved up 38% to $0.31 following the announcement.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
BELLUS Health Inc. (TSX:BLU), a Canadian biopharma stock, climbed 21% to $11.40 on Thursday after announcing that it has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in patients with refractory chronic cough.
, higher on Thursday.){kind=link}